rupiya.io
⠋Loading...
0%
❯ Pulling quarterly results...
Cian Healthcare Ltd is a Drug Manufacturers - Specialty & Generic company listed on BSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Cian Healthcare Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Sales | ₹57 Cr | ₹74 Cr | ₹78 Cr | ||
| Expenses | ₹50 Cr | ₹62 Cr | ₹74 Cr | ||
| Operating Profit | ₹7 Cr | ₹12 Cr | ₹4 Cr | ||
| OPM % | 13.0% | 16.0% | 6.0% | ||
| Other Income | ₹1 Cr | ₹0 Cr | ₹0 Cr | ||
| Depreciation | ₹4 Cr | ₹3 Cr | ₹4 Cr | ||
| Interest | ₹7 Cr | ₹8 Cr | ₹7 Cr | ||
| Profit Before Tax | ₹-4 Cr | ₹1 Cr | ₹-6 Cr | ||
| Tax | ₹-4 Cr | ₹1 Cr | ₹-6 Cr | ||
| Net Profit | ₹-4 Cr | ₹0 Cr | ₹-6 Cr | ||
| EPS (₹) | -1.6 | 0.0 | -2.2 | ||
| Dividend Payout % | 0% | 0% | 0% |
Register free to see 2 more years.
| Quarter | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹29 Cr | ₹28 Cr | ₹39 Cr | ₹35 Cr | ||||||
| Expenses | ₹26 Cr | ₹23 Cr | ₹34 Cr | ₹28 Cr | ||||||
| Operating Profit | ₹3 Cr | ₹4 Cr | ₹5 Cr | ₹7 Cr | ||||||
| OPM % | 10.0% | 15.0% | 13.0% | 20.0% | ||||||
| Depreciation | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ||||||
| Interest | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ||||||
| Net Profit | ₹-2 Cr | ₹-2 Cr | ₹-1 Cr | ₹1 Cr | ||||||
| EPS (₹) | -0.9 | -0.8 | -0.5 | 0.5 |
Register free to see 6 more quarters.
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹23 Cr | ₹23 Cr | ₹25 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹35 Cr | ₹35 Cr | ₹30 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹73 Cr | ₹71 Cr | ₹63 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹25 Cr | ₹28 Cr | ₹47 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹157 Cr | ₹157 Cr | ₹166 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹39 Cr | ₹37 Cr | ₹50 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹5 Cr | ₹5 Cr | ₹5 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹87 Cr | ₹90 Cr | ₹98 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹157 Cr | ₹157 Cr | ₹166 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 2 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2021 | ₹-7 Cr | ₹-27 Cr | ₹36 Cr | — |
| Mar 2022 | ₹6 Cr | ₹3 Cr | ₹-10 Cr | — |
| Mar 2023 | ₹9 Cr | ₹1 Cr | ₹-11 Cr | — |
| Mar 2024 | ||||
| Mar 2025 |
Register free to see 2 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.